Heparin vs Warfarin: Differences, Mechanism & GPAT Notes

Introduction to Anticoagulants in Hematology

Anticoagulants are life-saving drugs that prevent blood clot formation and prevent existing thrombi from enlarging. In human physiology, blood coagulation is a strictly regulated enzymatic cascade. It balances clot formation (hemostasis) and clot dissolution (fibrinolysis).

In clinical practice and pharmacy entrance exams like GPAT, NIPER, and pharmacist recruitment tests, heparin and warfarin are the two most frequently tested hematological drugs. While both serve as blood thinners, their chemical natures, mechanisms, routes, and reversal agents are completely different.

---

Heparin: Mechanism, Types, and Pharmacology

Heparin is a naturally occurring glycosaminoglycan with a strong negative charge. It is extracted commercially from porcine intestinal mucosa or bovine lung tissue.

Mechanism of Action

Heparin does not have intrinsic enzymatic activity. Instead, it acts indirectly by binding to a circulating serine protease inhibitor called Antithrombin III (AT-III).

• Heparin binds to AT-III through a specific pentasaccharide sequence.
• This binding causes a conformational change in AT-III, accelerating its inhibitory action by nearly 1,000-fold.
• Activated AT-III primarily inactivates Factor IIa (Thrombin) and Factor Xa, along with Factors IXa, XIa, and XIIa.

Unfractionated Heparin (UFH) vs Low Molecular Weight Heparin (LMWH)

• Unfractionated Heparin (UFH): Large molecular weight (5,000 to 30,000 Da). It wraps around both AT-III and Thrombin in a ternary complex to inhibit Thrombin (Factor IIa) and Factor Xa in an equal 1:1 ratio.
• Low Molecular Weight Heparins (LMWH): Examples include Enoxaparin, Dalteparin, and Tinzaparin (average weight 4,000 to 6,000 Da). Due to shorter chain lengths, LMWHs cannot easily wrap around thrombin. They selectively inhibit Factor Xa over Factor IIa (ratio roughly 3:1 to 4:1).

Key Pharmacokinetic Features

• Route: Intravenous (IV) or Subcutaneous (SC). Never given intramuscularly (IM) due to the risk of hematoma.
• Onset: Immediate following IV injection.
• Placental transfer: Heparin is a large, negatively charged molecule. It does not cross the placenta, making it the anticoagulant of choice during pregnancy.

---

Warfarin: Mechanism, Metabolism, and Clinical Pearls

Warfarin is an oral synthetic derivative of 4-hydroxycoumarin. It is structurally related to bishydroxycoumarin (dicumarol), which was discovered in spoiled sweet clover.

Mechanism of Action

Warfarin acts as an indirect, competitive inhibitor of the enzyme Vitamin K Epoxide Reductase Complex 1 (VKORC1).

1. Clotting factors II, VII, IX, and X (as well as regulatory proteins C and S) require post-translational gamma-carboxylation of glutamic acid residues to become functionally active.
2. This carboxylation requires the reduced form of Vitamin K (hydroquinone).
3. In this reaction, Vitamin K is oxidized into Vitamin K epoxide.
4. Warfarin blocks VKORC1, preventing the regeneration of active Vitamin K.
5. As a result, biologically inactive clotting factors accumulate.

Onset and Duration

• Warfarin has a delayed onset of action (36 to 72 hours). It does not affect clotting factors already present in the circulation.
• The clinical effect depends on the degradation half-lives of existing factors:
  • Factor VII: Shortest half-life (~6 hours).
  • Factor IX: ~24 hours.
  • Factor X: ~36 to 48 hours.
  • Factor II (Prothrombin): Longest half-life (~60 to 72 hours).
• Anticoagulation is fully established only when Prothrombin levels drop significantly.

Teratogenicity

• Warfarin is a lipophilic, small molecule that readily crosses the placenta.
• It is strictly contraindicated in pregnancy (Pregnancy Category X). It causes Fetal Warfarin Syndrome (nasal hypoplasia, stippled epiphyses, and central nervous system defects).

---

Laboratory Monitoring: aPTT vs PT/INR

Monitoring anticoagulant therapy prevents both underdosing (thrombosis) and overdosing (fatal hemorrhage).

Monitoring Heparin

• Test: Activated Partial Thromboplastin Time (aPTT).
• Target: aPTT measures the integrity of the intrinsic and common coagulation pathways. Therapeutic target is 1.5 to 2.5 times the normal control value (normal baseline is 30 to 40 seconds).
• LMWH generally does not require routine laboratory monitoring due to predictable bioavailability. If needed, anti-Factor Xa levels are measured.

Monitoring Warfarin

• Test: Prothrombin Time (PT), reported as the International Normalized Ratio (INR).
• Target: PT evaluates the extrinsic and common pathways (especially Factor VII). For most indications (e.g., deep vein thrombosis, atrial fibrillation), the target INR is 2.0 to 3.0. For mechanical prosthetic heart valves, the target INR is 2.5 to 3.5.

---

Comparison Table: Heparin vs Warfarin

Feature	Heparin (UFH)	Warfarin
Chemical Nature	Glycosaminoglycan (Large polymer)	4-Hydroxycoumarin derivative
Source	Biological (Porcine/Bovine tissue)	Synthetic
Route of Administration	Parenteral only (IV / SC)	Oral
Site of Action	In vitro and In vivo	In vivo only
Mechanism	Activates Antithrombin III	Inhibits VKORC1 enzyme
Target Factors	IIa, Xa, IXa, XIa, XIIa	II, VII, IX, X, Protein C & S
Onset of Action	Rapid (Minutes)	Slow (3 to 5 days)
Monitoring Parameter	aPTT (Intrinsic pathway)	PT / INR (Extrinsic pathway)
Specific Antidote	Protamine Sulfate	Vitamin K1 (Phytonadione)
Safety in Pregnancy	Safe (Does not cross placenta)	Teratogenic (Avoid)
Major Adverse Effects	Bleeding, HIT, Osteoporosis	Bleeding, Skin necrosis, Teratogenicity

---

Toxicity, Adverse Effects, and Antidotes

Heparin-Induced Thrombocytopenia (HIT)

• HIT Type II is a serious immune-mediated reaction. IgG antibodies target the complex of heparin and Platelet Factor 4 (PF4).
• This leads to platelet activation, profound thrombocytopenia, and paradoxical life-threatening thrombosis.
• Treatment: Immediately stop heparin. Switch to a direct thrombin inhibitor such as Argatroban, Bivalirudin, or Fondaparinux.

Specific Antidotes for Overdose

• Heparin Antidote: Protamine Sulfate. It is a strongly basic, positively charged fish-derived peptide. It forms an inactive, stable salt with strongly acidic heparin via electrostatic neutralization. (1 mg of protamine neutralizes approximately 100 units of heparin).
• Warfarin Antidote: Vitamin K1 (Phytonadione) given orally or slowly IV. In cases of severe, life-threatening hemorrhage, Vitamin K acts too slowly. Clinicians administer Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) for rapid reversal.